Dyne Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Dyne Therapeutics, Inc. (DYN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $16.62 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-29
- Dyne Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $16.03, a 30.96% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $12.24, a 51.72% decline year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $25.35, a 95.00% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $13.00, a 46.89% increase year-over-year.
- Dyne Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $11.66, a 61.82% decline from fiscal 2024.
- Dyne Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $30.54, a 165.10% increase from fiscal 2023.
- Dyne Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $11.52, a 17.55% increase from fiscal 2022.
- Dyne Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $9.80, a 38.13% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.62 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | $16.03 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $11.66 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $10.44 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $10.88 10-Q · filed 2025-07-28 | |||
| 2025-03-31 | $12.24 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $30.54 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $31.25 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $26.90 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $25.35 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $11.52 10-K · filed 2024-03-05 | |||
| 2023-09-30 | $12.38 10-Q · filed 2023-10-30 | |||
| 2023-06-30 | $12.65 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $13.00 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $9.80 10-K · filed 2023-03-02 | |||
| 2022-09-30 | $8.24 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $7.06 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $8.85 10-Q · filed 2022-05-02 | |||
| 2021-12-31 | $15.84 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $18.15 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $18.30 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $17.70 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $7.13 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $6.94 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |